Vigabatrin, sold under the brand name Sabril, is an anticonvulsant medication used to manage and treat infantile spasms (West syndrome) and refractory complex partial seizures in patients who have not responded to other treatments. Vigabatrin works by inhibiting the enzyme gamma-aminobutyric acid transaminase (GABA-T), leading to increased levels of γ-aminobutyric acid (GABA), a neurotransmitter that helps suppress seizure activity in the brain.
Parent: Vigabatrin
Parent: Vigabatrin
Parent: Vigabatrin
Parent: Vigabatrin
Controlling impurities in vigabatrin is critical to ensure the safety, efficacy, and quality of the medication. Impurities may arise during synthesis, storage, or handling.
Related Substances
These are chemically related compounds formed during the manufacturing process of vigabatrin. Strict limits are placed on these substances to ensure the drug’s purity and therapeutic effectiveness.
Degradation Products
Vigabatrin may degrade when exposed to light, moisture, or heat. Proper storage in its original packaging and at recommended temperatures is essential to maintain its stability.
Residual Solvents
Trace amounts of solvents used during synthesis may remain in the final product. Regulatory guidelines ensure these levels are within safe limits to avoid any risks to patients.
Analytical Techniques for Monitoring Impurities
Techniques such as High-Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC) are employed to detect and quantify impurities, ensuring compliance with stringent quality standards.
Vigabatrin is an anticonvulsant medication used for infantile spasms and refractory complex partial seizures. It is highly effective but carries a risk of significant side effects, including permanent vision loss. Regular eye exams are required during treatment to monitor for potential vision issues.
The most serious adverse effect of vigabatrin is permanent bilateral concentric visual field loss, which is often irreversible. This risk necessitates regular vision monitoring through visual field testing.
Vigabatrin is contraindicated in patients with:
Vigabatrin carries a black box warning due to the risk of permanent vision loss, including tunnel vision and reduced visual acuity. This warning highlights the importance of regular visual monitoring during treatment and careful risk-benefit consideration before starting the medication.
